Literature DB >> 29234213

Progress in Nanomedicine: Approved and Investigational Nanodrugs.

C Lee Ventola.   

Abstract

Nanomedicine is a relatively new and rapidly evolving field combining nanotechnology with the biomedical and pharmaceutical sciences.1-3 Nanoparticles (NPs) can impart many pharmacokinetic, efficacy, safety, and targeting benefits when they are included in drug formulations.1-5 Many nanodrugs have entered clinical practice, and even more are being investigated in clinical trials for a wide variety of indications.2 However, nanopharmaceuticals also face challenges, such as the need for better characterization, possible toxicity issues, a lack of specific regulatory guidelines, cost-benefit considerations, and waning enthusiasm among some health care professionals. 4,5 For these reasons, expectations regarding nanodrugs that are in early stages of development or clinical trials need to remain realistic.4.

Entities:  

Year:  2017        PMID: 29234213      PMCID: PMC5720487     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  60 in total

Review 1.  Dendrimers in biomedical applications--reflections on the field.

Authors:  Sönke Svenson; Donald A Tomalia
Journal:  Adv Drug Deliv Rev       Date:  2005-11-21       Impact factor: 15.470

2.  A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

Authors:  Francine M Foss; Nelida Sjak-Shie; Andre Goy; Eric Jacobsen; Ranjana Advani; Mitchell R Smith; Rami Komrokji; Kelly Pendergrass; Vanessa Bolejack
Journal:  Leuk Lymphoma       Date:  2013-01-29

Review 3.  Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.

Authors:  Joseph M Caster; Artish N Patel; Tian Zhang; Andrew Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-06-16

4.  Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.

Authors:  Praveen Elamanchili; Manish Diwan; Min Cao; John Samuel
Journal:  Vaccine       Date:  2004-06-23       Impact factor: 3.641

5.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

6.  Ultrafine Particle-Mediated Activation of Macrophages: Intracellular Calcium Signaling and Oxidative Stress.

Authors:  V Stone; D M Brown; N Watt; M Wilson; K Donaldson; H Ritchie; W MacNee
Journal:  Inhal Toxicol       Date:  2000-01       Impact factor: 2.724

Review 7.  Clinical experience with denileukin diftitox (ONTAK).

Authors:  Francine Foss
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

8.  Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Authors:  Jorge E Cortes; Stuart L Goldberg; Eric J Feldman; David A Rizzeri; Donna E Hogge; Melissa Larson; Arnaud Pigneux; Christian Recher; Gary Schiller; Krzysztof Warzocha; Hagop Kantarjian; Arthur C Louie; Jonathan E Kolitz
Journal:  Cancer       Date:  2014-09-15       Impact factor: 6.860

Review 9.  Nanopharmaceuticals (part 1): products on the market.

Authors:  Volkmar Weissig; Tracy K Pettinger; Nicole Murdock
Journal:  Int J Nanomedicine       Date:  2014-09-15

Review 10.  Nanopharmaceuticals (part 2): products in the pipeline.

Authors:  Volkmar Weissig; Diana Guzman-Villanueva
Journal:  Int J Nanomedicine       Date:  2015-02-11
View more
  192 in total

1.  Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors:  Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Authors:  Ibra S Fancher; Israel Rubinstein; Irena Levitan
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 3.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 4.  Focus on Fundamentals: Achieving Effective Nanoparticle Targeting.

Authors:  Gregory T Tietjen; Laura G Bracaglia; W Mark Saltzman; Jordan S Pober
Journal:  Trends Mol Med       Date:  2018-06-05       Impact factor: 11.951

Review 5.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 6.  Let's get small (and smaller): Combining zebrafish and nanomedicine to advance neuroregenerative therapeutics.

Authors:  David T White; Meera T Saxena; Jeff S Mumm
Journal:  Adv Drug Deliv Rev       Date:  2019-02-12       Impact factor: 15.470

Review 7.  Application of the combinatorial approaches of medicinal  and aromatic plants with nanotechnology and its impacts on healthcare.

Authors:  Priyanka Kumari; Suaib Luqman; Abha Meena
Journal:  Daru       Date:  2019-05-25       Impact factor: 3.117

8.  Self-assembly of four generations of RNA dendrimers for drug shielding with controllable layer-by-layer release.

Authors:  Xin Li; Mario Vieweger; Peixuan Guo
Journal:  Nanoscale       Date:  2020-07-30       Impact factor: 7.790

9.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

10.  Simulation-directed amplifiable nanoparticle enhanced quantitative scattering assay under low magnification dark field microscopy.

Authors:  Dali Sun; Li Yang; Christopher J Lyon; Tony Hu
Journal:  J Mater Chem B       Date:  2020-07-01       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.